

August 2023

## Quick-Start Protocol

# Reverse Transcriptase

Reverse Transcriptase (cat. no. RT32-010) is a modified, recombinant form of the Reverse Transcriptase from Moloney Murine Leukemia Virus (M-MuLV) purified from *E. coli*. Reverse Transcriptase synthesizes a complementary DNA strand in the presence of a primer using either RNA (cDNA synthesis) or single-stranded DNA (ssDNA) as a template.

Reverse Transcriptase is shipped on dry ice. All components should be stored at  $-20^{\circ}\text{C}$  in a freezer without a defrost cycle.

### Further information

- Safety Data Sheets: [www.qiagen.com/safety](http://www.qiagen.com/safety)
- Technical assistance: [support.qiagen.com](http://support.qiagen.com)

### Notes before starting

- Acquisition of high quality, intact RNA, free of genomic DNA and RNase traces, is vital for the synthesis of full-length cDNA followed by an accurate quantitative analysis (qPCR). The following recommendations for working with RNA should therefore be followed:
  - Maintain aseptic working conditions: use disposable gloves, changing them as frequently, as required; use RNase-free consumables; only work in an area assigned for working with RNA and with equipment designated for that purpose.

- RNA samples should be stored aliquoted at  $-70^{\circ}\text{C}$ . Avoid subjecting the samples to repeated freezing and thawing cycles.
- During RT-PCR preparation keep Reverse Transcriptase and **10x RT Reaction Buffer** on ice or in a freezing rack.
- Use an RNase H treatment for reactions sensitive to residue RNA traces in order to increase the sensitivity of RT-qPCR.
- The quantity of cDNA used when preparing PCR or qPCR reactions should not exceed 1/10 of a final reaction volume; e.g., a maximum volume of 2.5  $\mu\text{L}$  of cDNA should be used in a 25  $\mu\text{L}$  reaction.
- The activity of Reverse Transcriptase is inhibited by metal ion chelating agents (e.g., EDTA), inorganic phosphors, pyrophosphates and polyamines.
- **Enzyme inactivation** should be carried out at  $85^{\circ}\text{C}$  for 5 min.

## Protocol for the first strand cDNA synthesis

1. Add all reaction reagents listed below to a sterile nuclease-free tube placed on ice or in a freezing rack (for a larger quantity of samples, preparing Master Mix without an RNA template is recommended). The reagents should be added in the following order:

**Table 1. Reagents to be added and corresponding quantities**

	Reagent	Quantity
RNA	Total RNA	10 $\mu\text{g}$ – 5 $\mu\text{g}$
	mRNA	10 $\mu\text{g}$ – 500 ng
Primer	oligo(dT) <sub>12–18</sub> primer mix	1 $\mu\text{L}$ (50 $\mu\text{M}$ )
	or random hexamers	1 $\mu\text{L}$ (50–250 ng)
	or specific primers	1 $\mu\text{L}$ (pmol)
Nucleotides	10 mM dNTP MIX	1 $\mu\text{L}$ (final conc. 0.5 mM)
Water	Nuclease-free water	Fill up to 16 $\mu\text{L}$

**Optional:** For denaturation, incubate the sample at  $65^{\circ}\text{C}$  for 5 min, cool on ice, spin briefly, and return to ice. This denaturation step is necessary if GC-rich templates containing secondary structures are used.

2. Add the reagents listed below to the sample in the order tabulated below.

**Table 2. Order of reagents to be added to the sample**

Reagent	Quantity
10x RT Reaction Buffer	2 $\mu$ L
RNase Inhibitor (optional, not provided)	1 $\mu$ L (40 U)
Reverse Transcriptase	1 $\mu$ L (200 U)
Total volume	20 $\mu$ L

3. Mix gently and spin briefly.

**Optional:** Incubate sample at 25°C for 10 min. If random hexamers are used, this step is mandatory.

4. Incubate at 50°C for 30 min.

5. Stop the reaction at 85°C for 5 min and immediately cool the sample on ice.

6. The cDNA obtained is ready for direct use in PCR or qPCR (undiluted or diluted in nuclease-free water or TE buffer) or can be stored at -20°C or -70°C.

## Document Revision History

Date	Changes
August 2023	Initial release

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual.

Trademarks: QIAGEN®, Sample to Insight® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

08/2022 HB-3444-001 © 2023 QIAGEN, all rights reserved.